CLYM · Climb Bio, Inc.

Climb Bio, Inc. delivered Q1 2026 financial results reflecting disciplined cost management, with R&D expenses dropping 46% year-over-year to $9.4 million, primarily due to the absence of a $9 million upfront license payment to Beijing Mabworks Biotech Co., Ltd. for CLYM116 made in the prior year. G&A expenses remained stable at $5.8 million, contributing to a narrower net loss of $13.7 million or $(0.20) per share, compared to $20.8 million or $(0.31) per share in Q1 2025. Other income, net declined slightly to $1.5 million. Balance sheet highlights include $146.3 million in cash, cash equivalents, and marketable securities as of March 31, 2026, down from $160.7 million at year-end 2025 but sufficient to fund operations into 2028 based on the pre-financing plan. The subsequent $110 million private placement on April 29, 2026, led by top-tier healthcare investors, significantly bolsters liquidity ahead of key 2026 data readouts. CEO Aoife Brennan emphasized execution on a focused strategy for budoprutug, an anti-CD19 monoclonal antibody, and CLYM116, an anti-APRIL antibody. Key clinical progress includes robust B-cell depletion with budoprutug's subcutaneous formulation in Phase 1 healthy volunteers, mirroring IV results and supporting a planned multiple-dose autoimmune patient study. Enrollment proceeds in PrisMN Phase 2 for primary membranous nephropathy (FDA Fast Track granted), Phase 1b/2a for immune thrombocytopenia, and Phase 1b for systemic lupus erythematosus, with initial data anticipated in June and Q4 2026. For CLYM116, Phase 1 safety data and modeling will be presented at ERA 2026, with PK/PD data expected mid-2026. These milestones position Climb Bio to generate critical proof-of-concept data across high-unmet-need immune-mediated indications, enhancing long-term value creation for investors.